AI Article Synopsis
- - The study aimed to assess the prevalence of ventilator-associated events (VAE) and the antibiotic resistance patterns of bacterial infections in ventilator-associated pneumonia (VAP) within an ICU in Uttarakhand, highlighting VAP as a major cause of hospital-acquired infections (HAI).
- - A total of 1,220 patients were monitored; 6.4% were diagnosed with VAE, which progressed to different infection-related conditions, with the significant presence of certain bacteria among the isolates.
- - Effective early antibiotic treatment is crucial for improving patient outcomes, with colistin being the most effective antibiotic against the detected organisms, although challenges in diagnosing VAP remain.
Article Abstract
Background And Objectives: Despite progress in diagnosing and managing ventilator-associated pneumonia (VAP), ongoing monitoring of ventilator-associated events (VAE) is crucial due to VAP's persistent prominence as the primary cause of Hospital-Acquired Infection (HAI) among Intensive Care unit patients. This study was done to illuminate the prevalence of VAE and antibiogram of bacterial isolates of VAP in a tertiary care hospital of Uttarakhand.
Materials And Methods: This cross-sectional study focused on ICU patients. Adult patients ventilated for > 2 days were monitored daily, with VAE data analyzed using Center of Disease Control & Prevention (CDC) criteria. Specimens were sent to the Microbiology Department and cultured on Blood agar and MacConkey agar. Identification and antimicrobial profiles of isolates were determined using Vitek-2 Compact.
Results: 1220 ventilated individuals were assessed in total. VAE was diagnosed in 6.4% (78/1220) of the patients, the same later developed ventilator associated condition (VAC), 74 developed the infection-related VAC (IVAC), and 60 developed the possible/probable VAP (PVAP) among the 78 VAE cases. (35%), (33%), and (16%) were the most common isolated organisms. Colistin (57%) was the most effective against followed by amikacin (28.5%) and trimethoprim+sulfamethoxazole (24%). was most susceptible to imipenem (70%), meropenem, cefoperazone+sulbactam, and colistin (60%). was most susceptible to colistin (85%), tigecycline (65%), and trimethoprim+sulfamethoxazole (25%).
Conclusion: The most common cause of HAI is VAP. The purpose of this study is to determine the importance of starting suitable antibiotics early for prognosis and the difficulty of diagnosing VAP.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751612 | PMC |
| http://dx.doi.org/10.18502/ijm.v15i6.14137 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Naso-intestinal versus gastric tube for enteral nutrition in patients undergoing mechanical ventilation: a systematic review and meta-analysis.
Syst Rev
January 2025
Department of Neurosurgery, Pingxiang People's Hospital, Pingxiang, Jiangxi Province, 337000, China.
Background: A systematic appraisal of the comparative efficacy and safety profiles of naso-intestinal tube versus gastric tube feeding in the context of enteral nutrition for mechanically ventilated (MV) patients is imperative. Such an evaluation is essential to inform clinical practice, ensuring that the chosen method of nutritional support is both optimal and safe for this patient population.
Methods: We executed an exhaustive search across PubMed et al.
A phase III randomized controlled non-inferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) versus piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).
Int J Infect Dis
December 2024
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Electronic address:
Objectives: Imipenem/cilastatin/relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor combination effective against gram-negative pathogens. Efficacy and safety of IMI/REL were studied in critically ill adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).
Methods: In this phase III, double-blind, multinational, randomized trial (NCT03583333), adults with HABP/VABP were randomized 1:1 to receive intravenous IMI/REL (500 mg/250 mg) or piperacillin/tazobactam (PIP/TAZ; 4000 mg/500 mg) every 6 h for 7-14 days.
Enhancing critical care practitioners' knowledge and adherence to ventilator-associated events bundle: a comprehensive analysis.
Front Med (Lausanne)
November 2024
Department of Health Administration, College of Business Administration, King Saud University Riyadh, Riyadh, Saudi Arabia.
Objectives: Few surveys have focused on ventilator-associated pneumonia occurring in critically ill patients undergoing intubation and mechanical ventilation. Limited knowledge among healthcare workers may impede compliance with evidence-based guidelines for preventing ventilator-associated pneumonia. We evaluate the knowledge of intensive care professionals related to preventing ventilator-associated pneumonia in the intensive care units.
View Article and Find Full Text PDFClinical trial to verify the safety of an automatic electric airway suction system: a multicenter prospective randomized study.
Eur J Med Res
November 2024
Division of Acute Care Surgery, Department of Surgery, Korea University Anam Hospital, 73 Goryeodae-ro Seongbuk-gu, Seoul, 02841, Republic of Korea.
Article Synopsis
- The study assessed the safety of the Lmeca.A1000 automatic suction device compared to manual suctioning in ICU patients suffering from acute lung injury and respiratory failure.
- A multicenter, randomized trial involving 117 critically ill adults showed no significant differences in mucosal injury or pneumonia rates between the two methods.
- The findings suggest that the automatic suction device is safe and could reduce the workload for healthcare professionals without compromising airway management effectiveness.
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature.
Immunotherapy
December 2024
Medical Oncology Department of Gastrointestinal Tumors, Liaoning Key Laboratory of Gastrointestinal Cancer Translational Reasearch, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, China.
Cytokine release syndrome (CRS) is an uncommon but deadly side effect of immune checkpoint inhibitors (ICIs). ICIs are presently an increasingly important therapy option for malignant tumors, but there are limited treatments available for CRS. We present a case of a 72-year-old man who received one cycle of ICI coupled with cisplatin and albumin-binding paclitaxel therapy for a locally advanced right lung adenocarcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!